Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Huvepharma has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is concentrated under 1 distinct examiner and 1 distinct art unit, indicating that the company's current prosecution efforts are highly localized. For a practitioner, this means there is no administrative complexity from multiple examiners or different art unit standards. The prosecution strategy can be entirely focused on the specific practices of the 1 distinct art unit.
The busiest examiner for this portfolio is BUCKMASTER, MARLENE VRENI, who is responsible for 1 busiest examiner pending action. Since the total pending office actions count is 1, BUCKMASTER, MARLENE VRENI is the sole examiner currently handling the company's active prosecution. This allows the practitioner to focus all their efforts on a single interaction at the USPTO. The outcome of the pending matter will be determined by the specific examination approach of BUCKMASTER, MARLENE VRENI within the 1 distinct art unit. This concentration allows for a more direct and efficient prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUCKMASTER, MARLENE VRENI | 1 | 25.8% | +78.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17602923 | RECOMBINANT CIRCOVIRUS CAPSID-VIRUS-LIKE PARTICLE (VLP): COMPOSITIONS, METHODS AND USES | BUCKMASTER, MARLENE VRENI | 89d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17602923 | RECOMBINANT CIRCOVIRUS CAPSID-VIRUS-LIKE PARTICLE (VLP): COMPOSITIONS, METHODS AND USES | BUCKMASTER, MARLENE VRENI | 89d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17602923 | RECOMBINANT CIRCOVIRUS CAPSID-VIRUS-LIKE PARTICLE (VLP): COMPOSITIONS, METHODS AND USES | BUCKMASTER, MARLENE VRENI | 1672 | §103 | Non-Final OA | 89d overdue | Pending | Oct 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial